Results 151 to 160 of about 74,948 (336)

Weizmannia coagulans XY2 Mitigates Copper Neurotoxicity via Gut–Brain Axis Modulation of Tryptophan Metabolism and Oxidative‐Inflammatory Crosstalk

open access: yesiMetaOmics, EarlyView.
Copper interferes with tryptophan metabolism and 5‐HT levels by modulating intestinal flora. Intestinal barrier breakdown and inflammatory response trigger nerve damage under copper exposure. W. coagulans XY2 alleviates copper‐induced neurotoxicity by targeting a multi‐dimensional “tryptophan metabolism‐antioxidant defense‐gut‐brain axis” network.
Yufang Gao, Xiaodong Zheng, Fujie Yan
wiley   +1 more source

Inhibition of Ubc13-mediated ubiquitination by GPS2 regulates multiple stages of B cell development [PDF]

open access: yes, 2016
Non-proteolytic ubiquitin signaling mediated by Lys63 ubiquitin chains plays a critical role in multiple pathways that are key to the development and activation of immune cells.
Aggarwal   +122 more
core   +1 more source

Loganin, an Iridoid Glycoside, Alleviates Paclitaxel‐Induced Skeletal Muscle Toxicity by Enhancing Mitochondrial Function, Boosting Antioxidant Defenses, and Reducing Cellular Senescence

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Mitochondrial dysfunction and energy imbalance caused by chemotherapy are key contributors to skeletal muscle atrophy, which severely impacts the quality of life in cancer patients. Paclitaxel, a commonly used chemotherapeutic agent, is known to promote muscle wasting and cellular senescence, largely by impairing mitochondrial function.
Yu‐Fan Chuang   +6 more
wiley   +1 more source

Screening for Novel Genes Contributing to the Transformed Status of Alveolar Rhabdomyosarcoma (ARMS) [PDF]

open access: yes, 2012
Alveolar rhabdomyosarcoma (ARMS) is the second most common subtype of rhabdomyosarcoma, accounting for approximately 20% of cases. ARMS is associated with the chromosomal translocations t(2;13)(q35;q14) and t(1;13)(p36;q14) resulting in the fusion ...
Picchione, F. (Fabrizio)
core  

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

open access: yes, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello   +3 more
core   +1 more source

Case Report of Maxillary Alveolar Rhabdomyosarcoma Misdiagnosed as Periapical Lesion: Clinicopathological Alerts and Life‐Saving Lessons for Dentists

open access: yesAustralian Endodontic Journal, EarlyView.
ABSTRACT This report describes a rare case of alveolar rhabdomyosarcoma initially presenting with clinical features resembling an endodontic lesion. A 15‐year‐old male presented with progressive right maxillary swelling initially treated as a dental abscess.
Saliha Akçay Köprücü   +3 more
wiley   +1 more source

Heat Shock Protein 20 (HSP20) is a novel substrate for Protein Kinase D1 (PKD1) [PDF]

open access: yes, 2015
Heat shock protein 20 (HSP20) has cardioprotective qualities, which are triggered by PKA phosphorylation. PKD1 is also a binding partner for HSP20, and this prompted us to investigate whether the chaperone was a substrate for PKD1.
Baillie, George, Sin, Yuan Yan
core   +1 more source

Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab

open access: yesCancer Science, EarlyView.
This study found immune markers that may predict how well patients with advanced lung cancer respond to atezolizumab. Higher levels of certain T cells were linked to better survival. Specific patterns suggested a worse prognosis for some patients. ABSTRACT We investigated immunologic biomarkers that predict outcomes of patients with previously treated ...
Atsuto Mouri   +24 more
wiley   +1 more source

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy

open access: yesOncoImmunology, 2018
Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating
Beata Pyrzynska   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy